ATENOLOL EXPOSURE AS RISK FOR ADVERSE METABOLIC RESPONSES TO BETA BLOCKERS

阿替洛尔暴露可能导致β受体阻滞剂不良代谢反应的风险

• 批准号: 7950759
• 负责人: Julie E. Johnson
• 金额: $ 0.47万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950759
• 关键词: Adrenergic beta-Antagonists; Adverse effects; Americas; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cardiovascular system; Clinical; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Data; Diabetes Mellitus; Diuretics; Dose; Essential Hypertension; Funding; Grant; Heart failure; Hypertension; Institution; Kidney Failure; Lipids; Metabolic; Morbidity - disease rate; Myocardial Infarction; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Patients; Plasma; Reporting; Research; Research Personnel; Resources; Risk; Risk Factors; Source; Stroke; United States; United States National Institutes of Health; Weight Gain; cardiovascular risk factor; diabetic; hypertension treatment; insulin sensitivity; mortality; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cardiovascular disease-CVD is the leading cause of mortality in the United States of America and hypertension is an important cardiovascular risk factor. It is also a risk factor for stroke, heart attack, renal failure and heart failure. Beta-blockers along with diuretics are among the recommended first-line agents for the treatment of hypertension. Data from various studies indicate that the risk of developing diabetes in hypertensive patients is related to the antihypertensive drug strategy. Type 2 diabetes comprises ~ 90% of new cases of diabetes and occurs in 60% of hypertensive patients. Beta-blockers and diuretics have been used for the treatment of hypertension for decades and have been shown to decrease cardiovascular morbidity and mortality rates in patients with essential hypertension. One of the arguments against the primary use of beta-blockers has been the concern about adverse metabolic effects on the lipid profile and on insulin sensitivity. Another side effect is the propensity of beta-blockers to cause weight gain. Obesity is now well recognized as an important predictor of overall mortality. Increased body weight is a clinical problem in the vast majority of hypertensive patients and almost all type 2 diabetic hypertensive patients. Although, various reports indicate low doses of diuretics to be free from negative effects on the lipid profile and insulin sensitivity; no such studies are reported for the beta-blockers. Through this study we will determine concentration response relationship between the occurrence of metabolic effects and beta-blocker systemic plasma concentrations.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 心血管疾病-CVD是美国死亡率的主要原因，高血压是重要的心血管危险因素。 它也是中风、心脏病发作、肾衰竭和心力衰竭的危险因素。 β受体阻滞剂沿着利尿剂是推荐的治疗高血压的一线药物。 各种研究数据表明，高血压患者发生糖尿病的风险与降压药物策略有关。 2型糖尿病占新发糖尿病病例的约90%，发生在60%的高血压患者中。 β受体阻滞剂和利尿剂已用于治疗高血压数十年，并已被证明可降低原发性高血压患者的心血管发病率和死亡率。 反对主要使用β受体阻滞剂的一个论点是担心对血脂和胰岛素敏感性的不良代谢作用。 另一个副作用是β受体阻滞剂导致体重增加的倾向。 肥胖现在被公认为是总体死亡率的一个重要预测因素。 体重增加是绝大多数高血压患者和几乎所有2型糖尿病高血压患者的临床问题。 尽管各种报告表明低剂量利尿剂对血脂和胰岛素敏感性无不良影响;但没有关于β受体阻滞剂的此类研究报告。 通过本研究，我们将确定代谢效应的发生与β受体阻滞剂全身血浆浓度之间的浓度响应关系。